Rwanda is currently grappling with its first-ever outbreak of the deadly Marburg virus. The disease, closely related to the Ebola virus, originates from fruit bats, exhibiting a mortality rate that can reach as high as 88%. Over 27 cases and nine deaths have been reported, causing global health agencies to categorize the risk of this outbreak as high at national and regional levels.
Unfortunately, there are currently no known treatments or vaccines for the Marburg virus. However, some supportive care measures, such as intravenous fluid administration, can be beneficial. Marburg patients generally present symptoms like high fever and blood in vomit or stool, indicating severe viral hemorrhagic fever caused by various harmful viruses like Ebola or yellow fever.
Health experts harbor particular concern for this outbreak in Rwanda due to the swift diagnosis of numerous Marburg patients soon after the outbreak’s announcement. The quick succession of diagnosis indicates that the virus had been circulating for a few weeks before detection. This timeline can be attributed to the lack of prior Marburg cases in Rwanda, leading healthcare professionals initially to overlook this prospect during patient examinations. Preventative measures are now in full effect, including rigorous personal protective equipment protocols and widespread public handwashing stations.
Transmissions from bats usually occur through contact with bat urine, excretions, or consumption of fruit contaminated by bats. However, past outbreaks have occasionally occurred without direct bat contact. Consequently, researchers speculate that intermediate hosts, such as monkeys or pigs, pass the virus on to humans. Despite this, it remains difficult for the virus to wildly spread because it is not airborne, and patients usually perish quickly.
The extensive exposure of healthcare workers to the Marburg patients in Rwanda is also alarming. The possibility of misdiagnosing Marburg-stricken individuals due to symptom similarities with other diseases could have caused these healthcare professionals to forego the necessary protective gear. Currently, Rwandan officials are implementing strategies to counter this situation by monitoring about 300 contacts of Marburg patients.
Potential response measures involving community health workers visiting patient homes for testing have also been discussed. The broad reach of this outbreak is worrisome as patients have been identified in seven out of Rwanda’s 30 districts, including the capital city Kigali. The risk of quick human transmission and viral spread via transportation is particularly high, especially considering the reported case of a person traveling from Rwanda to Belgium after contact with a Marburg patient.
Despite the challenges presented, the potential for studying and testing potential Marburg vaccines during this outbreak must be acknowledged. Rwanda’s robust health system and its capacity to control this outbreak also provide some source of optimism. Nevertheless, the country’s simultaneous handling of other health emergencies, including an ongoing mpox outbreak, presents additional hurdles.